



| OneHP

ONE HIGH-POTENT PLATFORM
ULTRA-HIGH CONTAINMENT

From milligram discovery to
multi-kilogram cGMP supply,
your high-potent molecule
never leaves the facility.



One Platform. Multiple Advantages



Reduce Risk

No vendor handoffs,
no revalidation cycles



Ensure Continuity

Scalability and containment
engineered in from day one



Accelerate Timelines

Knowledge follows your
molecule, from milligrams
to kilograms

HIGH-POTENT MOLECULES | PAYLOADS & LINKERS | BIOCONJUGATION



OneHP unifies high-potent molecule discovery, development, analytical, & GMP manufacturing on a single integrated platform.

Aragen brings 10+ years of HPAPI experience across oncology, autoimmune, hormonal, antiviral and other potent therapeutic areas



Discovery

Hit identification to preclinical candidate nomination, safely at a single site



Process Development

Scale-up to de-risk GMP transition




GMP Manufacturing

Clinical & commercial batches up to 5kg



Analytical & QC

In-house method development, validation & testing



Supported modalities: small-molecule cytotoxics & kinase inhibitors, ADC payloads & linkers (auristatins, maytansinoids, PBDs), PROTACs & molecular glues, potent peptides, and oligonucleotides.

Stage Scale

Discovery chemistry	1mg to 10gm
Process development & scale-up	10mg to 500gm
GMP manufacturing	500gm – 5kg per batch



~15,000

Sq ft OEB-6 facility



OEL

Up to 10ng/m³ ultra-high containment



5

Levels of cascading protection



500–600 kg

Annual capacity

Our OEB-6 facility delivers safe, world-class HPAPI manufacturing through advanced containment, expert cross-functional teams, and compliance with US FDA, EMA, PMDA and DCGI standards. EDGE-certified for sustainability, it offers the therapeutic versatility and scalable infrastructure to take your project from route scouting to commercial supply.



Info@aragen.com



www.aragen.com